References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395(10223):497-506.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine 2020 Feb 28.
3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020 Feb 7.
4. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Feb 22;395(10224):565-74.
5. Weekly Operational Update on COVID-1926 April 2021. World Health Organization; 2021 Apr 26. Informe N.º; 52.
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. Jama 2020 Apr 7;323(13):1239-42.
7. Gobierno de España, Ministerio de Sanidad, Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III. Situación de COVID-19 en España [Internet]. Apr 2020. Available from: https://covid19.isciii.es/.
8. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine 2020 Mar 13.
9. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. The lancet Gastroenterology & hepatology 2020 Mar 4.
10. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver international : official journal of the International Association for the Study of the Liver 2020 Mar 14.
11. Xie H, Zhao J, Lian N, et al. Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injuryA Retrospective study. Liver international : official journal of the International Association for the Study of the Liver 2020 Apr 2.
12. Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver international : official journal of the International Association for the Study of the Liver 2020 Apr 2.
13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 Feb 15;395(10223):507-13.
14. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. Journal of hepatology 2020 Sep;73(3):566-74.
15. Lei F, Liu YM, Zhou F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology 2020 Aug;72(2):389-98.
16. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology 2020 Jul;5(7):667-78.
17. Ampuero J, Sanchez-Torrijos Y, Garcia Lozano MDR, et al. Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 2020 Dec 3.
18. Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerging infectious diseases 2004 May;10(5):818-24.
19. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020 Mar 4.
20. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 Mar;579(7798):270-3.
21. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology 2020 Oct;73(4):807-16.
22. Gobierno de España, Ministerio de Sanidad, Instituto de Salud Carlos III. Procedimiento de actuación frente a casos de infección por el nuevo coronavirus (SARS-CoV-2). [updated 30 March 2020] 40 p.
23. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases [Internet]. 2020 [updated 17 Jan 2020] Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
24. Belsley D. Conditioning Diagnostics: Collinearity and Weak Data in Regression. New York: Wiley; 1991. 396 p.
25. Boyer TD, Manns MP, Sanyal AJ. Zakim and Boyer’s Hepatology. 6th ed. Philadelphia: Elsevier Saunders; 2012. 1314 p.
26. Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004 Feb;39(2):302-10.
27. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. The New England journal of medicine 2003 May 15;348(20):1986-94.
28. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. The New England journal of medicine 2003 May 15;348(20):1977-85.
29. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science Human Protein Atlas. Available from: http://www.proteinatlas.org. 2015 Jan 23;347(6220):1260419.
30. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of pathology 2004 Jun;203(2):631-7.
31. Lopinavir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [Updated 2017 Sep 1].